Drug Trial Radar · NCT04562389
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
353
Actual
Start
Mar 11, 2021
Primary completion
Feb 20, 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of the study comparing the efficacy and safety of combination therapy of selinexor + ruxolitinib with combination of placebo + ruxolitinib.
Conditions
- Myelofibrosis
Interventions
SelinexorDrug
Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
SelinexorDrug
Participants will receive a dose of 60 mg selinexor oral tablets QW.
PlaceboOther
Participants will receive a matching placebo of selinexor oral tablets QW
RuxolitinibDrug
Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) ScanTime frame: At Week 24
- Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0Time frame: At Week 24
- Phase 1: Maximum Tolerated Dose (MTD)Time frame: Approximately within the first cycle (28 days) of therapy
- Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Approximately within the first cycle (28 days) of therapy
- Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and SeverityTime frame: From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)
Locations
166 sites in 20 countries. Site status is shown where the registry gives one.
UAB Division of Hematology/Oncology
Birmingham, Alabama
UCLA - Satellite Site
Beverly Hills, California
City of Hope
Duarte, California
UCLA - Satellite Site
Encino, California
City of Hope - Irvine Lennar - Satellite
Irvine, California
UCLA
Los Angles, California
The Oncology Institute of Hope & Innovation
Pasadena, California
USOR - Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado
Smilow Cancer Hospital - New Haven
New Haven, Connecticut
Georgetown Lombardi Comprehensive Center
Washington D.C., District of Columbia
Norton Cancer Institute - Saint Matthews
Louisville, Kentucky
Maryland Oncology Hematology-Satellite
Annapolis, Maryland
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Maryland Oncology Hematology-Satellite
Brandywine, Maryland
Maryland Oncology Hematology
Columbia, Maryland
Maryland Oncology Hematology-Satellite
Rockville, Maryland
Maryland Oncology Hematology-Satellite
Silver Spring, Maryland
The Cancer & Hematology Centers -Satellite Site
Grand Rapids, Michigan
The Cancer & Hematology Centers of Muskegon
Norton Shores, Michigan
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai Health System
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke Cancer Institue
Durham, North Carolina
USOR - Oncology Hematology Care - Kenwood
Cincinnati, Ohio
Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
OhioHealth
Columbus, Ohio
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Texas Oncology
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
USOR - Virginia Cancer Specialists - Gainesville Office
Gainesville, Virginia
VCU Massey Cancer Center
Richmond, Virginia
USOR - Virginia Oncology Associates - Virginia Beach
Virginia Beach, Virginia
Fred Hutchinson Cancer Center - SCAA South Lake Union
Seattle, Washington
West Virginia University Cancer Institute, Wheeling Hospital
Wheeling, West Virginia
University of Wisconsin - Madison
Madison, Wisconsin
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Icon Cancer Centre - Wesley
South Brisbane, Queensland, Australia
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.